Cytochrome P450 — physiological key factor against cholesterol accumulation and the atherosclerotic vascular process

References

• Omura T., Sato R. The carbon‐monoxide‐binding pigment in liver microsomes. II. Solubilization, purification and properties. J Biol Chem 1964; 239: 2379–85
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Russell D. W. Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155–62
   PubMed Web of Science ®Google Scholar
• Luoma P. V., Sotaniemi E. A., Pelkonen R. O., Myllylä V. V. Plasma high density lipoprotein cholesterol and hepatic cytochrome P‐450 concentrations in epileptics undergoing anticonvulsant treatment. Scand J Clin Lab Invest 1980; 40: 163–7
   PubMed Web of Science ®Google Scholar
• Luoma P. V., Sotaniemi E. A., Pelkonen R. O., Ehnholm C. Plasma high density lipoprotein and liver microsomal enzyme activity in man. The Medical Research Council 1977–1979, A. S Pilli‐Sihvola, T. H Laaksovirta. The Academy of Finland, Helsinki 1980; 71
   Google Scholar
• Luoma P. V., Sotaniemi E. A., Pelkonen R. O., Arranto A., Ehnholm C. Plasma high density lipoproteins and hepatic microsomal induction—relation to histological changes in the liver. Eur J Clin Pharmacol 1982; 23: 275–82
   PubMedGoogle Scholar
• Luoma P. V., Sotaniemi E. A., Pelkonen R. O. Inverse relation of serum LDL cholesterol and the LDL/HDL cholesterol ratio to liver microsomal induction in man. Res Commun Chem Pathol Pharmacol 1983; 42: 173–6
   Google Scholar
• Luoma P. V., Sotaniemi E. A., Arranto A. J. Serum LDL cholesterol and LDL/HDL cholesterol ratio and liver microsomal induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest 1983; 43: 671–5
   Google Scholar
• Janowski B. A., Willy P. J., Devi T. R., Falck J. R., Mangelsdorf D. J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 1996; 383: 728–31
   PubMed Web of Science ®Google Scholar
• Lehmann J. M., Kliewer S. A., Moore L. B., Smith‐Oliver T. A., Oliver B. B., Su J. L., et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997; 272: 3137–40
   PubMed Web of Science ®Google Scholar
• Björkhem I., Andersson O., Diczfalusy U., Sefastik B., Xiu R. ‐J., Duan C., et al. Atherosclerosis and sterol 27‐hydroxylase: Evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A 1994; 91: 8592–6
   PubMed Web of Science ®Google Scholar
• Reiss A. B., Martin K. O., Javitt N. B., Martin D. W., Grossi E. A., Galloway A. C. Sterol 27‐hydroxylase: high levels of activity in vascular endothelium. J Lipid Res 1994; 35: 1026–30
   PubMed Web of Science ®Google Scholar
• Björkhem I., Diczfalusy U., Lütjohann D. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr Opin Lipidol 1999; 10: 161–5
   PubMed Web of Science ®Google Scholar
• Wang N., Silver D. L., Costet P., Tall A. R. Specific binding of apoA‐I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABCA1. J Biol Chem 2000; 275: 33053–8
   PubMed Web of Science ®Google Scholar
• Wang N., Lan D., Chen W., Matsuura F., Tall A. R. ATP‐binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high‐density lipoproteins. Proc Natl Acad Sci U S A 2004; 101: 9774–9
   PubMed Web of Science ®Google Scholar
• Klucken J., Büchler C., Orsó E., Kaminski W. E., Porsch‐Özcϋrϋmez M., Liebisch G., et al. ABCG1 (ABC8), the human homolog of the drosophila white gene, is regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A 2000; 97: 817–22
   PubMed Web of Science ®Google Scholar
• Luoma P. V. Gene activation, apolipoprotein A‐I/ high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol 1997; 81: 57–64
   PubMedGoogle Scholar
• Luoma P. V., Savolainen M. J., Sotaniemi E. A., Pelkonen R. O., Arranto A. J., Ehnholm C. Plasma high density lipoprotein and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction. Acta Med Scand 1983; 214: 103–9
   Google Scholar
• Chao Y. U., Pickett C. B., Yamin T. T., Guo L. S., Alberts A., Kroon P. A. Phenobarbital induces rat liver apoliprotein A‐I mRNA. Mol Pharmacol 1985; 27: 394–8
   PubMedGoogle Scholar
• Malmendier C. L., Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clinica Chimica Acta 1985; 152: 281–8
   PubMed Web of Science ®Google Scholar
• Malmendier C., Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55: 161–9
   PubMed Web of Science ®Google Scholar
• Saku K., Gartside P. S., Hynd B. A., Kashyap M. L. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985; 75: 1702–12
   PubMed Web of Science ®Google Scholar
• Tam S. P. Effects of gemfibrozil and ketoconazole on human apolipoprotein A‐I and E levels in two hepatoma cell lines HepG2 and HepG3. Atherosclerosis 1991; 91: 51–61
   Google Scholar
• Tam S. P. Effect of ethanol on lipoprotein secretion in two human hepatoma cell lines HepG2 and HepG3. Alcohol Clin Exp Res 1992; 16: 1021–8
   Google Scholar
• Rubin E. M., Krauss M. R., Spangler E. A., Verstuyft J. G., Clift M. S. Inhibition of early atherogenesis in transgenic mice by human apoprotein A‐I. Nature 1991; 353: 265–7
   PubMed Web of Science ®Google Scholar
• Duverger N., Kruth N. H., Emmanuel F., Caillaud J. M., Viglietta C., Castro G., et al. Inhibition of atherosclerosis development in cholesterol‐fed human apolipoprotein A‐I transgenic rabbits. Circulation 1996; 94: 713–7
   PubMed Web of Science ®Google Scholar
• Eriksson M., Carlson L. A., Miettinen T. A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A‐I. Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594–8
   PubMed Web of Science ®Google Scholar
• Russell D. W. Oxysterol biosynthetic enzymes. Biochim Biophys Acta 2000; 1529: 126–35
   PubMed Web of Science ®Google Scholar
• Tontonoz P., Mangelsdorf D. J. Liver X receptors signalling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985–93
   PubMed Web of Science ®Google Scholar
• Ory D. S. Nuclear receptor signalling in the control of cholesterol homeostasis: have the orphans found a home. Circ Res 2004; 95: 660–70
   PubMed Web of Science ®Google Scholar
• Russell D. W. The enzymes, regulation and genetics of bile acid synthesis. Annu Rev Biochem 2003; 72: 137–74
   PubMed Web of Science ®Google Scholar
• Björkhem I., Diczfalusy U. Oxysterols–friends, foes or just fellow passengers. Arterioscler Thromb Vasc Biol 2002; 22: 734–42
   PubMed Web of Science ®Google Scholar
• Fu X., Menke J. G., Chen Y., Zhou G., MacNaul K. L., Wright S. D., et al. 27–hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol loaded cells. J Biol Chem 2001; 276: 38378–87
   PubMed Web of Science ®Google Scholar
• Escher G., Krozowski Z., Croft K. D., Sviridov D. Expression of sterol 27‐hydroxylase (CYP27A1) enhances cholesterol efflux. J Biol Chem 2003; 278: 11015–9
   PubMed Web of Science ®Google Scholar
• Norlin M., Andersson U., Björkhem I., Wikwall K. Oxysterol 7α‐hydroxylase activity by cholesterol 7α‐hydroxylase (CYP7A). J Biol Chem 2000; 275: 34046–53
   PubMed Web of Science ®Google Scholar
• Björkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; 24: 806–15
   PubMed Web of Science ®Google Scholar
• Dietschy J. M., Turley S. D. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004; 45: 1375–97
   PubMed Web of Science ®Google Scholar
• Lütjohann D., Breuer O., Ahlborg G., Nennesmo I., Sidén Å., Diczfalusy U., et al. Cholesterol homeostasis in human brain: Evidence for an age‐dependent flux of 24S‐hydroxycholesterol from the brain into circulation. Proc Natl Acad Sci U S A 1996; 93: 9799–804
   PubMed Web of Science ®Google Scholar
• Li‐Hawkins J., Lund E. G., Bronson A. D., Russell D. W. Expression cloning of an oxysterol 7α‐hydroxylase selective for 24‐hydroxycholesterol. J Biol Chem 2000; 275: 16543–48
   PubMed Web of Science ®Google Scholar
• Abildayeva K., Jansen P. J., Hirsch‐Reinshagen V., Bloks W. V., Bakker A. H. F., Ramaekers F. C. S., et al. 24(S)‐hydroxycholesterol participates in a liver X receptor‐controlled pathway in astrocytes that regulates apolipoprotein E‐mediated cholesterol efflux. J Biol Chem 2006; 281: 12799–808
   PubMed Web of Science ®Google Scholar
• Pfrieger F. W. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes. Bioessays 2002; 25: 72–8
   Web of Science ®Google Scholar
• Panzenboeck U., Balazs Z., Sovic A., Hrzenjak A., Levak‐Frank S., Wintersperger A., et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse cholesterol transport at an in vitro blood‐brain barrier constituted porcine brain capillary endothelial cells. J Biol Chem 2002; 277: 42781–9
   PubMed Web of Science ®Google Scholar
• Lütjohann D., Papassotiropoulos A., Björkhem I., Locatelli S., Bagli M., Oehring R. D., et al. Plasma 24S‐hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000; 41: 195–8
   PubMed Web of Science ®Google Scholar
• Bodin K., Bretillon L., Aden Y., Bertilsson L., Broome U., Einarsson C., et al. Antiepileptic drugs increase plasma levels of 4β‐hydroxycholesterol in humans. J Biol Chem 2001; 276: 38685–9
   PubMed Web of Science ®Google Scholar
• Gibbons G. F. The role of cytochrome P450 in the regulation of cholesterol biosynthesis. Lipids 2002; 37: 1163–70
   Google Scholar
• Ridgway N. D., Dawson P. A., Ho Y. K., Brown M. S., Goldstein J. L. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. J Cell Biol 1992; 116: 307–19
   Google Scholar
• Olkkonen V. M., Johansson M., Suchanek M., Yan D., Hynynen R., Ehnholm C., et al. The OSBP‐related proteins (ORPS): global sterol sensors for co‐ordination of cellular lipid metabolism, membrane trafficking and signalling processes. Biochem Soc Transact 2006; 34: 389–91
   Google Scholar
• Raychaudhuri S., Im Y. J., Hurley J. H., Prinz W. A. Nonvesicular sterol movement from plasma membrane to ER requires oxysterol‐binding protein related proteins and phosphoinositides. J Cell Biol 2006; 173: 107–19
   PubMedGoogle Scholar
• Chawla A., Boisvert W., Lee C. ‐H., Laffitte B. A., Barak Y., Joseph S. B., et al. A PPARγ– LXR–ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 161–71
   PubMed Web of Science ®Google Scholar
• Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., et al. The gene encoding ATP‐binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22: 347–51
   PubMed Web of Science ®Google Scholar
• Brooks‐Wilson A., Marcil M., Clee S. M., Zhang L. H., Roomp K., van Dam M., et al. Mutations in ABC1 in Tangier disease and familial high‐density lipoprotein deficiency. Nat Genet 1999; 22: 336–45
   PubMed Web of Science ®Google Scholar
• Rust S., Rosier M., Funke H., Real J., Amoura Z., Piett J. C., et al. Tangier disease is caused by mutations in the gene encoding ATP‐binding cassette transporter 1. Nat Genet 1999; 22: 352–5
   PubMed Web of Science ®Google Scholar
• Lawn R. M., Wade D. P., Garvin M. R., Wang X., Schwartz K., Porter J. G., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein‐mediated lipid removal pathway. J Clin Invest 1999; 104: R25–31
   PubMed Web of Science ®Google Scholar
• Tangirala R. K., Bischoff E. D., Joseph S. B., Wagner B. L., Walczak R., Laffitte B. A., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A 2002; 99: 11896–901
   PubMed Web of Science ®Google Scholar
• Schuster G. U., Parini P., Wang L., Alberti S. A., Steffensen K. R., Hansson G. K., et al. Accumulation of foam cells in liver X receptor‐deficient mice. Circulation 2002; 106: 1147–53
   PubMed Web of Science ®Google Scholar
• Singaraja R. R., Fievet C., Castro G., James E. R., Hennuyer N., Clee S. M., et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002; 110: 35–42
   PubMed Web of Science ®Google Scholar
• Brewer H. B., Jr, Remaley A. T., Neufeld E. B., Basso F., Jouce C. Regulation of plasma high‐density lipoprotein levels by the ABCA1 transporter and the emerging role of high‐density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1755–60
   PubMed Web of Science ®Google Scholar
• Timmins J. M., Lee J. ‐Y., Boydyguina E., Kluckman K. D., Brunham L. R., Mulya A., et al. Targeted inactivation of hepatic Abc 1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA‐I. J Clin Invest 2005; 115: 1333–42
   PubMed Web of Science ®Google Scholar
• Brunham L. R., Kruit K. J., Iqbal J., Fievet C., Timmins J. M., Pape T., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006; 116: 1052–62
   PubMed Web of Science ®Google Scholar
• Repa J. J., Turley S. D., Lobaccaro J. A., Medina J., Li L., Lustig K., et al. Regulation of absorption of ABCA1‐mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524–9
   PubMed Web of Science ®Google Scholar
• Yu L., Li‐Hawkins J., Hammer R. E., Berge K. E., Horton J. D., Cohen J. C., et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest 2002; 110: 671–80
   PubMed Web of Science ®Google Scholar
• Kruit J. K., Plösch T., Havinga R., Boverhof R., Groot P. E. H., Groen A. K., et al. Increased fecal neutral steroid loss upon liver‐X‐receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 2005; 128: 147–56
   PubMed Web of Science ®Google Scholar
• Berge K. E., Tian H., Graf G. A., Yu L., Grishin N. V., Schutz J., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771–5
   PubMed Web of Science ®Google Scholar
• Chinetti G., Lestavel S., Bocher V., Remaley A. T., Neve B., Torra I. P., et al. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53–8
   PubMed Web of Science ®Google Scholar
• Li A. C., Glass C. K. PPAR‐ and LXR‐dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 2004; 45: 2161–73
   PubMed Web of Science ®Google Scholar
• Mak P. A., Laffitte B. A., Resrumaux C., Joseph S. B., Curtiss L. K., Mangelsdorf D. J., et al. Regulated expression of the apolipoproteinE/C‐I/C‐IV/C‐CII gene cluster in murine and human macrophage. A critical role for nuclear liver X receptors α and β. J Biol Chem 2002; 277: 31900–8
   PubMed Web of Science ®Google Scholar
• Duverger N., Tremp G., Caillaud J. M., Emmanuel F., Castro G., Fruchart J. M., et al. Protection against atherogenesis in mice mediated by human apolipoprotein AIV. Science 1996; 273: 966–8
   PubMedGoogle Scholar
• Liang Y., Jiang X. ‐C., Liu R., Liang G., Beyer T. P., Gao H., et al. Liver X receptors (LXRs) regulate apolipoprotein AIV—implications of the antiatherosclerotic effect of LXR agonists. Mol Endocrinol 2004; 18: 2000–10
   Google Scholar
• Repa J. J., Liang G., Ou J., Bashmakov Y., Lobaccaro J. M. A., Shimomura I., et al. Regulation of mouse sterol regulatory element‐binding protein‐1c (SREBP‐1c) by oxysterol receptors LXRα and LXRβ. Genes Dev 2000; 14: 2819–30
   PubMed Web of Science ®Google Scholar
• Horton J. D., Goldstein J. L., Brown M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–31
   PubMed Web of Science ®Google Scholar
• Malerod L., Juvet L. K., Hanssen‐Bauer A., Eskild W., Berg T. Oxysterol‐activated LXRalpha/RXR induces hSR‐BI‐promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun 2002; 299: 916–23
   PubMedGoogle Scholar
• Ji Y., Jian B., Wang N., Sun Y., de la Llera Moya M., Phillips M. C., et al. Scavenger receptor BI promotes high density lipoprotein‐mediated cellular cholesterol efflux. J Biol Chem 1997; 272: 20982–5
   PubMed Web of Science ®Google Scholar
• Eloranta J. J., Kullak‐Ublick G. A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 2005; 433: 397–412
   PubMed Web of Science ®Google Scholar
• Claudel T., Staels B., Kuipers F. The farnesoid X receptor—a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020–31
   PubMed Web of Science ®Google Scholar
• Bodin K., Lindbom U., Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta 2005; 1687: 84–93
   PubMed Web of Science ®Google Scholar
• Goodwin B., Moore J. T. CAR: detailing new models. Trends Pharmacol Sci 2004; 25: 437–41
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T., Richards K. M., Qui Y., Strong‐Basalyga K., Miller A., Li C., et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharmaceut Res 2005; 22: 71–8
   PubMed Web of Science ®Google Scholar
• Amacher D., Beck D., Schomaker S. J., Kenny C. V. Hepatic microsomal enzyme induction, β‐oxidation, and cell proliferation following administration of clofibrate, gemfibrozil or bezafibrate in the CD rat. Toxicol Appl Pharmacol 1997; 142: 143–50
   PubMed Web of Science ®Google Scholar
• Kocarek T., Dahn M. S., Cai H., Strom S. C., Mercer‐Haines N. A. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 2002; 30: 1400–5
   PubMed Web of Science ®Google Scholar
• Kobayashi K., Yamanaka Y., Iwazaki N., Nakajo I., Hosokawa M., Negishi M., et al. Identification of HMG‐CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 2005; 33: 924–9
   PubMed Web of Science ®Google Scholar
• Fan P., Zhang B., Kuroki S., Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme A reductase inhibitor, increases cholesterol 7α‐hydroxylase gene expression in HepG2 cells. Circ J 2004; 68: 1061–6
   PubMed Web of Science ®Google Scholar
• Sahi J., Black C. B., Hamilton G. A., Zheng X., Jolley S., Rose K. A., et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31: 439–46
   PubMed Web of Science ®Google Scholar
• Lieber C. S. To drink (moderately) or not to drink?. N Engl J Med 1984; 310: 846–8
   PubMed Web of Science ®Google Scholar
• Luoma PV Sotaniemi E. A., Pelkonen R. O., Ehnholm C. High‐density lipoproteins and hepatic microsomal enzyme induction in alcohol consumers. Res Commun Chem Pathol Pharmacol 1982; 37: 91–6
   Google Scholar
• Reiss A. B., Rahman M., Chan E. S., Montesinos C., Awadallah N. W., Cronstein B. N. Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leucoc Biol 2004; 76: 727–34
   Web of Science ®Google Scholar
• Langmann T., Liebisch G., Moehle C., Schifferer R., Dayoab R., Heiduczek S., et al. Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim Biophys Acta 2005; 1740: 155–61
   PubMed Web of Science ®Google Scholar
• Staels B., Dallongville D., Auwerx J., Schhoonjans K., Leitersdorf E., Fruchart J. C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088–93
   PubMed Web of Science ®Google Scholar
• Arakawa R., Tamehiro N., Nishimaki‐Mogami T., Ueda K., Yokoyama S. Fenofibric acid, an active form of fenofibrate increases apolipoprotein A‐I‐mediated high‐density lipoprotein biogenesis by enhancing transcription of ATP‐binding cassette transporter AI gene in a liver X receptor‐dependent manner. Arterioscler Thromb Vasc Biol 2005; 25: 1193–7
   PubMed Web of Science ®Google Scholar
• Knight B. L., Patel D. D., Humphreys S. M., Wiggins D., Gibbons G. F. Inhibition of cholesterol absorption associated with a PPARα‐dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 2003; 44: 2049–58
   Google Scholar
• Guan J. ‐Z., Tamasava N., Murakami H., Matsui J., Yamato K., Suda T. Clofibrate, a peroxisome‐proliferator, enhances reverse cholesterol transport through cytochrome P450 activation and oxysterol generation. Tohoku J Exp Med 2003; 201: 251–9
   Google Scholar
• Argmann C. A., Edwards J. Y., Sawyez C. G., O'Neil C. H., Hegele R. A., Pickering J. G., et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl‐CoA reductase inhibition. J Biol Chem 2005; 280: 22212–21
   Google Scholar
• Maejima T., Yamazaki H., Aoki T., Tamaki T., Sato F., Kitahara M., et al. Y. Effect of pitavastatin on apolipoprotein A‐I production in HepG2 cell. Biochem Biophys Res Commun 2004; 324: 835–9
   PubMed Web of Science ®Google Scholar
• Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J. C., et al. Statin‐induced inhibition of the Rho‐signaling pathway activates PPARα and induces HDL apoA‐I. J Clin Invest 2001; 107: 1423–32
   PubMed Web of Science ®Google Scholar
• Lehmann J. M., McKee D. D., Watson M. A., Willson T. M., Moore J. T., Kliewer S. A. Human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016–23
   PubMed Web of Science ®Google Scholar
• Fajas L., Schoonjans K., Gelman L., Kim J. B., Najib J., Martin G., et al. Regulation of peroxisome proliferator‐activated receptor gamma expression by adipocyte differentation and determination factor1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999; 19: 5495–503
   PubMed Web of Science ®Google Scholar
• Glueck C. J. Nonpharmacologic and pharmacologic alteration of high‐density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am Heart J 1985; 110: 1107–15
   PubMedGoogle Scholar
• Shepherd J. The effect of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 1979; 33: 433–44
   PubMed Web of Science ®Google Scholar
• Forman B. M., Tontonoz P., Chen J., Brun R. P., Spiegelman B. M., Evans R. M. 15‐deoxy‐Δ 12,14‐prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83: 803–12
   PubMed Web of Science ®Google Scholar
• Lehmann J. M., Moore L. B., Smith‐Oliver T. A., Wilkison W. O., Wilson T. M., Kliewer S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator‐activated receptor PPARγ. J Biol Chem 1995; 270: 12953–6
   PubMed Web of Science ®Google Scholar
• Myers C. D., Kashyap M. L. Pharmacological augmentation of high‐density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 2005; 20: 307–12
   Google Scholar
• Akiyama T. E., Sakai S., Lambert G., Nicol C. J., Matsusue K., Pimprale S., et al. Conditional disruption of the peroxisome proliferator‐activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1 and apo E in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002; 22: 2607–19
   PubMed Web of Science ®Google Scholar
• Chinetti G., Gbaguidi F. G., Griglio S., Mallat Z., Antonucci M., Poulain P., et al. CLA‐1/SR‐BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator‐activated receptors. Circulation 2000; 101: 2411–7
   PubMed Web of Science ®Google Scholar
• Szanto A., Benko S., Szatmari I., Balint L. B., Furtos I., Rϋhl R., et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator‐activated receptor, and liver X receptor signalling in macrophages. Mol Cell Biol 2004; 24: 8154–66
   PubMed Web of Science ®Google Scholar
• Quinn C. M., Jessup W., Wong J., Kritharides L., Brown A. J. Expression and regulation of sterol 27‐hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARγ ligands. Biochem J 2005; 385: 823–30
   PubMed Web of Science ®Google Scholar
• Luo G., Cunningham M., Kim S., Burn T., Lin J., Sinz M., et al. 3A4 induction by drugs: correlation between a pregnane x receptor receptor gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Disp 2002; 30: 795–802
   PubMed Web of Science ®Google Scholar
• Moore L. B., Parks D. J., Jonest S. A., Bledsoe R. K., Consler T. G., Stimmel J. B., et al. Orphan nuclear receptors constitutive androstane receptor and Pregnane receptor share xenobiotic and steroid ligands. J Biol Chem 2000; 275: 15122–7
   PubMed Web of Science ®Google Scholar
• Makishima M., Lu T. T., Xie W., Whitfield G. K., Domoto H., Evans R. M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313–6
   PubMed Web of Science ®Google Scholar
• Beulens J. W., Sierksma A., van Tol A., Fournier N., van Gent T., Paul J. ‐L., et al. Moderate alcohol consumption increases cholesterol efflux mediated by ABCA1. J Lipid Res 2004; 45: 1716–23
   Google Scholar
• Costet P., Lalanne F., Gerbod‐Gionnone M., Molina J. R., Fu X., Lund E. G., et al. Retinoid acid receptor‐mediated induction of ABCA1 in macrophages. Mol Cell Biol 2003; 23: 7756–66
   PubMed Web of Science ®Google Scholar
• Astrup P., Kjeldsen K., Wanstrup J. Effects of carbon monoxide exposure on the arterial walls. Ann NY Acad Sci 1970; 174: 294–300
   PubMed Web of Science ®Google Scholar
• Haustein K. O., Krause J., Haustein H., Rasmussen T., Cort N. Comparison of the effects of combined nicotine replacement therapy vs. cigarette smoking in males. Nicotine Tob Res 2003; 5: 195–203
   Google Scholar
• Moffatt R. J., Stamford B. A., Biggerstaff K. D. Influence of worksite tobacco smoke on serum lipoprotein profiles of female nonsmokers. Metabolism 1995; 44: 1536–9
   Google Scholar
• Hedblad B., Ögren M., Engström G., Wollmer P., Janzon L. Heterogeneity of cardiovascular risk among smokers is related to degree of carbon monoxide exposure. Atherosclerosis 2005; 179: 177–83
   PubMed Web of Science ®Google Scholar
• Reiss A. B., Patel C. A., Rahman M. M., Chan E. S. L., Hasneen K., Montesinos M. M., et al. Interferon‐γ impedes reverse cholesterol transport and promotes foam cell transformation in TPH‐1 human monocytes/macrophages. Med Sci Monit 2004; 10: BR420–5
   Google Scholar
• Williams J. F. Cytochrome isoforms. Regulation during infection, inflammation and by cytokines. J Fla Med Assoc 1991; 78: 517–9
   PubMedGoogle Scholar
• Panousis V. G., Zuckerman S. H. Interferon‐γ induces downregulation of Tangier disease gene (ATP‐binding cassette transporter 1) in macrophage derived foam cells. Arterioscler Thromb Vasc Biol 2000; 20: 1565–71
   PubMed Web of Science ®Google Scholar
• von Bahr S., Movin T., Papadogiannakis N., Pikuleva I., Rönnow P., Diczfalusy U., et al. Mechanism of accumulation of cholesterol and cholestanol in tendons and the role of sterol 27‐hydroxylase (CYP27A1). Arterioscler Thromb Vasc Biol 2002; 22: 1129–35
   PubMed Web of Science ®Google Scholar
• Pullinger C. R., Eng C., Salen G., Shefer S., Barra A. K., Erickson S. K., et al. Human cholesterol 7α‐hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110: 109–17
   PubMed Web of Science ®Google Scholar
• Frick M. H., Syvänne M., Nieminen M. S., Kauma H., Majahalme S., Virtanen V., et al. Prevention of the angiographic progression of coronary vein‐graft atherosclerosis by gemfibrozil after coronary by‐pass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96: 2137–43
   PubMed Web of Science ®Google Scholar
• Ericsson C. G., de Faire U., Grip L., Svane B., Hamsten A., Nilsson J. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849–53
   PubMed Web of Science ®Google Scholar
• Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–10
   PubMed Web of Science ®Google Scholar
• Effect of simvastatin on coronary atheroma. The Multicentre Anti‐Atheroma Study (MAAS). Lancet 1994; 344: 633–8
   PubMed Web of Science ®Google Scholar
• Blankenhorn D. H., Azen S. P., Kramsch D. M., Mack W. J., Cashin‐Hemphill L., Hodis H. N., , the MARS Research Group, et al. Coronary angiographic changes with lovastatin therapy; The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969–76
   PubMed Web of Science ®Google Scholar
• Watts G. F., Lewis B., Brunt J. N. H., Lewis E. s., Coltart D. J., Smith L. D., et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine. In St Thomas Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563–9
   PubMed Web of Science ®Google Scholar
• Langenfeld M. R., Forst T., Hohberg C., Kann P., Lubben G., Konrad T., et al. Pioglitazone decreases carotid intima‐media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation 2005; 111: 2525–31
   PubMed Web of Science ®Google Scholar
• Myasnikov A. L. Influence of some factors on development of experimental cholesterol atherosclerosis. Circulation 1958; 17: 99–113
   PubMed Web of Science ®Google Scholar
• Salvador R. A., Atkins C., Haber S., Kozma C., Conney A. H. Effect of phenobarbital and chlorcyclizine on the development of atheromatosis in the cholesterol‐fed rabbit. Biochem Pharmacol 1970; 19: 1975–81
   Google Scholar
• Kiehl S., Willeit J., Rungger G., Egger G., Oberhollenzer F., Bonora E., et al. Alcohol consumption and atherosclerosis: What is the relation. Prospective results from the Bruneck study. Stroke 1998; 29: 900–7
   Google Scholar
• Femia R., Natali A., L'Abbate A., Ferrannini E. Coronary atherosclerosis and alcohol consumption. Angiographic and mortality data. Arterioscler Thromb Vasc Biol 2006; 26: 1607–12
   Google Scholar
• Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle‐aged men with dyslipidemia. New Engl J Med 1987; 317: 1237–45
   PubMed Web of Science ®Google Scholar
• Tenkanen L., Mänttäri M., Kovanen P. T., Virkkunen H., Manninen V. Gemfibrozil in the treatment of dyslipidemia. An 18‐year follow‐up of the Helsinki Heart Study. Arch Intern Med 2006; 166: 743–8
   PubMed Web of Science ®Google Scholar
• Keech A., Simes R. J., Barter J., Best J., Scott R., Taskinen M. R., et al. Effects of long‐term fenofibrate therapy on cardiovascular events in 9759 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet 2005; 366: 1849–61
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360: 7–22
   PubMed Web of Science ®Google Scholar
• Cheung B. M. Y., Lauder I. J., Lau C. ‐P., Kumana C. Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640–51
   PubMed Web of Science ®Google Scholar
• Baigent C., Keech A., Kearney P. M., Blackwell L., Buck G., Pollicino C., , Cholesterol Treatment Trialists' (CTT) Collaborators, et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial: results. I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351–64
   PubMed Web of Science ®Google Scholar
• Dormandy J. A., Charbonnel B., Eckland D. A. J., Erdmann E., Massi‐Benedetti M., Moules I. K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–89
   PubMed Web of Science ®Google Scholar
• Poikolainen K. Alcohol and mortality: a review. J Clin Epidemiol 1995; 48: 455–65
   Google Scholar
• Luoma P. V., Savolainen MJ., Sotaniemi E. A., Arranto A. J., Pelkonen R. O. Plasma HDL cholesterol and blood glucose in non‐insulin‐dependent diabetics related to liver lipids and microsomal enzyme activity. Acta Med Scand 1985; 217: 473–9
   Google Scholar
• Luoma P. V., Rautio A., Stengård J., Sotaniemi E. A., Marniemi J. High‐density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects. Eur J Clin Pharmacol 1990; 38: 625–7
   Google Scholar
• Tokola O., Pelkonen O., Karki N. T., Luoma P. Hepatic drug‐oxidizing enzyme systems and urinary D‐glucaric acid excretion in patients with congestive heart failure. Br J Clin Pharmacol 1975; 2: 429–36
   PubMedGoogle Scholar
• Luoma P. V., Myllylä V. V., Hokkanen E. Relationship between plasma high‐density lipoprotein cholesterol and anticonvulsant levels in epileptics. J Cardiovasc Pharmacol 1982; 4: 1024–7
   Google Scholar
• LaPorte R., Valvo‐Gerard L., Kuller L., Wanju R., Bates M., Cresanta J., et al. The relationship between alcohol consumption, liver enzymes and high‐density lipoprotein cholesterol. Circulation 1981; 64(suppl III)67–72
   Google Scholar
• Steyn K., Fourie J., Benade A. J., Roussow J. E., Langenhoven M. L., Joubert G., et al. Factors associated with high density lipoprotein cholesterol in a population with high high density lipoprotein cholesterol levels. Arteriosclerosis 1989; 9: 390–7
   Google Scholar
• Dixon R. M., Borden E. C., Keim N. L., Anderson S., Spennetta T. L., Tormey D. C., et al. Decreases in serum high‐density‐lipoprotein cholesterol and total cholesterol resulting from naturally produced recombinant DNA‐derived leucocyte interferon. Metabolism 1984; 33: 400–4
   PubMed Web of Science ®Google Scholar
• Andrade R. J., Escolar J. L., Valdivielso P., Gonzelez‐Santos P. Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. Drug Alcohol Depend 1990; 26: 161–8
   Google Scholar
• Robertson R. G., Krause B. R., Welty D. F., Wolfgang G. H. I., Grazian M. J., Pilcher G. D., et al. Hepatic microsomal induction profile of carbamic acid [[2,6‐bis(1‐methylethyl) phenoxy] sulfonyl]‐2,6‐bis(1‐methylethyl) phenyl ester, monosodium salt (PD138142‐15), a novel lipid regulating agent. Biochem Pharmacol 1995; 49: 799–808
   Google Scholar
• Evans R. M. The nuclear receptor superfamily: a rosette stone for physiology. Mol Endocrinol 2005; 19: 1429–38
   PubMed Web of Science ®Google Scholar
• Luoma P. V., Sotaniemi E. A., Ehnholm C. Low high‐density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. Scand J Gastroenterol 1980; 15: 869–73
   PubMed Web of Science ®Google Scholar
• Luoma P. V., Sotaniemi E. A., Pelkonen R. O., Pirttiaho H. I. Serum low density and high density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 1985; 28: 615–8
   Google Scholar
• Bretillon L., Lütjohann D., Ståhle L., Widhe T., Bindl L., Eggertsen G., et al. Plasma levels of 24S‐hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res 2000; 41: 840–5
   PubMed Web of Science ®Google Scholar
• Lehrke M., Lebherz C., Millington S. C., Guan H. P., Millar J., Rader D. J., et al. Diet‐dependent cardiovascular lipid metabolism controlled by hepatic LXRα. Cell Metab 2005; 1: 297–308
   PubMed Web of Science ®Google Scholar
• Joseph S. B., Mckilligan E., Pei L., Watson M. A., Collins A. R., Laffitte B. A., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002; 99: 7604–9
   PubMed Web of Science ®Google Scholar
• Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., et al. T‐0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice. FEBS Lett 2003; 536: 6–11
   PubMed Web of Science ®Google Scholar
• Kovanen P. T., Pentikäinen M. O. Pharmacological evidence for a role of liver X receptors in atheroprotection. FEBS Lett 2003; 536: 3–5
   PubMed Web of Science ®Google Scholar
• Levin N., Bischoff E. D., Daige C. L., Thomas D., Vu C. T., Heyman R. A., et al. Macrophage liver X receptor is required for anti‐atherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005; 25: 135–42
   PubMed Web of Science ®Google Scholar
• Naik S. U., Wang X., Da Silva J. S., Jaye M., Macphee C. H., Reilly M. R., et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006; 113: 90–7
   PubMed Web of Science ®Google Scholar